Health Equity in Clinical Trials Best Practices Database

Recognizing that many companies in New Jersey and beyond are dedicated to increasing diversity in clinical trials, BioNJ created this platform where life sciences professionals can go to search best practices, ascertain successful strategies and learn about initiatives that are underway.

Select from below to see initiatives.

Initiative
Bristol Myers Squibbhttps://s25.q4cdn.com/566753351/files/design/bms-rebrand-logo.svgWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://investors.bms.com/iframes/press-releases/press-release-details/2023/Bristol-Myers-Squibb-Inducted-into-the-Billion-Dollar-Roundtable-Expands-Supplier-Diversity-Efforts/default.aspxBristol Myers Squibb Inducted into the Billion Dollar Roundtable, Expands Supplier Diversity EffortsBristol Myers Squibb Inducted into the Billion Dollar Roundtable, Expands Supplier Diversity EffortsBMS has been inducted into the Billion Dollar Roundtable. This milestone highlights BMS' longstanding history of taking purposeful action to advance health equity, foster a diverse and inclusive workplace, improve and increase the diversity in its clinical trials and expand the diversity among its supplier base.
Bristol Myers Squibbhttps://s25.q4cdn.com/566753351/files/design/bms-rebrand-logo.svgWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://www.roi-nj.com/2024/05/22/healthcare/bristol-myers-squibb-outlines-10-year-strategy-to-reach-patients-in-low-and-middle-income-countries/Bristol Myers Squibb Outlines 10-Year Strategy to Reach Patients in low- and Middle-Income CountriesBristol Myers Squibb said Wednesday that it is creating a 10-year plan — ASPIRE, or Accessibility, Sustainability, Patient-centric, Impact, Responsibility and Equity — to expand access to its therapies to more than 200,000 patients in low- and middle-income countries by 2033.Bristol Myers Squibb said it is creating a 10-year plan — ASPIRE, or Accessibility, Sustainability, Patient-centric, Impact, Responsibility and Equity — to expand access to its therapies to more than 200,000 patients in low- and middle-income countries by 2033.
Bristol Myers Squibbhttps://s25.q4cdn.com/566753351/files/design/bms-rebrand-logo.svgWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://2j5d9c.p3cdn1.secureserver.net/wp-content/uploads/2024/03/Bristol-Myers-Squibb-RD-diversity-plans-elements-.pdfStudy Diversity Plans OverviewKey elements of the study diversity plan.

Key elements of the study diversity plan. 

Bristol Myers Squibbhttps://s25.q4cdn.com/566753351/files/design/bms-rebrand-logo.svgWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://www.bms.com/about-us/responsibility/bristol-myers-squibb-foundation/our-focus-areas/diversity-in-clinical-trials.htmlDiversity in Clinical TrialsThe Robert A. Winn Diversity in Clinical Trials Award program, created by the Bristol Myers Squibb Foundation, develops clinical investigators who are racially and ethnically diverse or who are committed to increasing diversity in clinical trials, and exposes promising, underrepresented minority medical students to clinical research career pathways.

The Robert A. Winn Diversity in Clinical Trials Award program, created by the Bristol Myers Squibb Foundation, develops clinical investigators who are racially and ethnically diverse or who are committed to increasing diversity in clinical trials, and exposes promising, underrepresented minority medical students to clinical research career pathways.

Bristol Myers Squibbhttps://s25.q4cdn.com/566753351/files/design/bms-rebrand-logo.svgWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://www.bms.com/life-and-science/news-and-perspectives/improving-diversity-and-inclusion-across-the-patient-experience.htmlHow BMS is Closing the Diversity Gap in Clinical TrialsBristol Myers Squibb (BMS) is working hard to change that, and we’re gaining recognition as an industry leader in making clinical trials readily accessible to a broad range of patients around the world.

Bristol Myers Squibb (BMS) is working hard to change that, and we’re gaining recognition as an industry leader in making clinical trials readily accessible to a broad range of patients around the world. 

Otsukahttps://upload.wikimedia.org/wikipedia/commons/4/46/Otsuka_Holdings_logo.svgWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://www.mhanational.org/Mental Health America (MHA) with support from Otsuka America Pharmaceuticals, Launches Equity Impact Zones (EIZ) ProgramMental Health America (MHA) with support from Otsuka America Pharmaceuticals, Inc. launched a new program called Equity Impact Zones (EIZ). The EIZ program will help New Jersey communities implement and sustain solutions to address mental health equity gaps. 

Mental Health America (MHA) with support from Otsuka America Pharmaceuticals, Inc. launched a new program called Equity Impact Zones (EIZ). The EIZ program will help New Jersey communities implement and sustain solutions to address mental health equity gaps. 

BeiGenehttps://2j5d9c.p3cdn1.secureserver.net/wp-content/uploads/2024/02/BEIBENE.pngWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://reaganudall.org/news-and-events/announcements/regulatory-science-innovation-and-health-equity-fellowshipRegulatory Science, Innovation, and Health Equity Fellowship Established by Reagan-Udall Foundation for the FDAThe Reagan-Udall Foundation for the FDA is pleased to announce the launch of its Regulatory Science, Innovation, and Health Equity Fellowship Program. Increasing diversity in regulatory science serves to bring varied perspectives into the field and generate more meaningful results.

The Reagan-Udall Foundation for the FDA is pleased to announce the launch of its Regulatory Science, Innovation, and Health Equity Fellowship Program. Increasing diversity in regulatory science serves to bring varied perspectives into the field and generate more meaningful results. 

BeiGenehttps://2j5d9c.p3cdn1.secureserver.net/wp-content/uploads/2024/02/BEIBENE.pngWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://hkexir.beigene.com/news/the-max-foundation-beigene-and-the-beigene-foundation-announce-collaboration-to-advance-health-equity-by/b52d680b-1d1e-4bf3-8203-783c21441635/The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income CountriesThe Max Foundation and BeiGene announced a collaboration to provide access to BRUKINSA (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) in 29 low- and middle-income countries over the next three years.

The Max Foundation and BeiGene announced a collaboration to provide access to BRUKINSA (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) in 29 low- and middle-income countries over the next three years.

TransCeleratehttps://2j5d9c.p3cdn1.secureserver.net/wp-content/uploads/2024/03/TransCelerate.pngWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://www.transceleratebiopharmainc.com/wp-content/uploads/2023/03/Diversity_FDA-Diversity-Plan-Early-Insights-and-Considerations_March-2023-2.pdfDiversity of Participants in Clinical TrialsFDA Diversity Plan Early Insights and Considerations

FDA Diversity Plan Early Insights and Considerations

Bristol Myers Squibbhttps://s25.q4cdn.com/566753351/files/design/bms-rebrand-logo.svgWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://www.bms.com/our-stories/science-and-innovation/learning-for-better-clinical-trials.htmlAI and Multimodal Patient Data for Better, Faster Clinical TrialsAs artificial intelligence (AI) programs achieve exponential gains in power and sophistication, Bristol Myers Squibb is exploring ways to leverage these technologies at many stages of the drug development process. In May 2022, BMS entered into a multi-year, strategic collaboration with Owkin, initially focusing on cardiovascular diseases.As artificial intelligence (AI) programs achieve exponential gains in power and sophistication, Bristol Myers Squibb is exploring ways to leverage these technologies at many stages of the drug development process. In May 2022, BMS entered into a multi-year, strategic collaboration with Owkin, initially focusing on cardiovascular diseases.
PHRMAhttps://2j5d9c.p3cdn1.secureserver.net/wp-content/uploads/2023/12/Phrma.pngWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://phrma.org/Equity/clinical-trial-diversityEquitable Breakthroughs In Medicine DevelopmentEquitable Breakthroughs in Medicine Development, a first-of-its-kind, cross-collaborative, community-based effort, seeks to tackle systemic challenges to clinical trial participation and share our findings broadly to help drive change.

Equitable Breakthroughs in Medicine Development, a first-of-its-kind, cross-collaborative, community-based effort, seeks to tackle systemic challenges to clinical trial participation and share our findings broadly to help drive change.

Gileadhttps://2j5d9c.p3cdn1.secureserver.net/wp-content/uploads/2023/11/Gilead.pngWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://www.fiercebiotech.com/biotech/bristol-myers-squibb-foundation-unites-competition-effort-boost-diversity-among-trialGilead Unites with Bristol Myers Squibb Foundation to Boost Diversity Among Clinical Trial InvestigatorsGilead will contribute $14 million over four years to the Bristol Myers Squibb Foundation’s career development program, which centers on elevating physicians of color.

Gilead will contribute $14 million over four years to the Bristol Myers Squibb Foundation’s career development program, which centers on elevating physicians of color.

Gileadhttps://2j5d9c.p3cdn1.secureserver.net/wp-content/uploads/2023/11/Gilead.pngWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://www.gilead.com/news-and-press/press-room/press-releases/2024/2/gilead-announces-funding-initiative-to-support-hiv-prevention-antistigma-and-health-equity-efforts-for-black-cisgender-and-transgender-women-and-girGilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.Gilead Sciences, Inc. announced it is providing a total of $12.6 million in grant funding to 19 organizations working to improve the HIV landscape for Black women and girls in the United States. 

Gilead Sciences, Inc. announced it is providing a total of $12.6 million in grant funding to 19 organizations working to improve the HIV landscape for Black women and girls in the United States. 

Bristol Myers Squibbhttps://s25.q4cdn.com/566753351/files/design/bms-rebrand-logo.svgWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://news.bms.com/news/philanthropy/2023/The-Robert-A.-Winn-Diversity-in-Clinical-Trials-Award-Announces-Third-Group-of-Physicians-in-Program-to-Increase-Diversity-in-Clinical-Trials/default.aspxRobert A. Winn Diversity in Clinical Trials Career Development AwardThe Robert A. Winn Diversity in Clinical Trials Award Program aims to train, develop and mentor more than 308 clinical trialists and 308 medical students by 2027 who are diverse or who have a demonstrated commitment to clinical trial diversity.

The Robert A. Winn Diversity in Clinical Trials Award Program aims to train, develop and mentor more than 308 clinical trialists and 308 medical students by 2027 who are diverse or who have a demonstrated commitment to clinical trial diversity.

Johnson & Johnsonhttps://2j5d9c.p3cdn1.secureserver.net/wp-content/uploads/2023/10/JJ.pngWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://njbiz.com/johnson-johnson-launches-health-equity-innovation-challenge/Johnson & Johnson launches Health Equity Innovation ChallengeIn a bid to address health disparities across the U.S., Johnson & Johnson is seeking changemakers to develop solutions to help close gaps in racial health and mortality in some of the country’s biggest cities.In a bid to address health disparities across the U.S., Johnson & Johnson is seeking changemakers to develop solutions to help close gaps in racial health and mortality in some of the country’s biggest cities.
Johnson & Johnsonhttps://2j5d9c.p3cdn1.secureserver.net/wp-content/uploads/2023/10/JJ.pngWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://www.jnj.com/media-center/press-releases/johnson-johnson-expands-commitment-to-advance-health-equity-in-the-united-statesJohnson & Johnson Expands Commitment to Advance Health Equity in the United StatesJohnson & Johnson supports more than 100 community-led organizations in marginalized communities to provide resources and tools to advance accessible, quality health care in the U.S.Johnson & Johnson supports more than 100 community-led organizations in marginalized communities to provide resources and tools to advance accessible, quality health care in the U.S.
My Health Can't Waithttps://2j5d9c.p3cdn1.secureserver.net/wp-content/uploads/2023/09/my-health-cant-wait.pngWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://www.myhealthcantwait.com/My Health Can’t WaitJohnson & Johnson presents My Health Can’t Wait is a community wellness initiative expanding access to vital health information and support for Patients and caregivers in communities of color.Johnson & Johnson presents My Health Can’t Wait is a community wellness initiative expanding access to vital health information and support for Patients and caregivers in communities of color.
Modernahttps://files.constantcontact.com/971a6f79001/94bdbaf7-a6cf-4501-a3d4-d6b6856ce76a.pngDATA TYPES (e.g., electronic health records)https://www.modernatx.com/en-US/media-center/all-media/blogs/diseases-dont-discriminate-neither-should-clinical-researchDiversity & Inclusion in Clinical Trials: Building Moderna’s CapabilitiesHow Moderna is applying what was learned from its COVID-19 trial experience and how it is being applied to Moderna’s CMV Phase 3 study.

How Moderna is applying what was learned from its COVID-19 trial experience and how it is being applied to Moderna’s CMV Phase 3 study.

Parexelhttps://2j5d9c.p3cdn1.secureserver.net/wp-content/uploads/2023/12/Parexel.pngDATA TYPES (e.g., electronic health records)https://www.parexel.com/insights/report/patient-focused-drug-development/diversity-strategies/planning-early-diversity-helps-contain-costs-and-avoid-delaysPlanning Early for Diversity Helps Contain costs and Avoid DelaysHow creating a diversity plan early in development can make drug development more efficient.

How creating a diversity plan early in development can make drug development more efficient.

Multi-Regional Clinical Trialshttps://2j5d9c.p3cdn1.secureserver.net/wp-content/uploads/2023/12/Multi-Regional-Clinical-Trials.pngDATA TYPES (e.g., electronic health records)https://mrctcenter.org/diversity-in-clinical-research/tools/abd_toolkit/Accessibility by Design (AbD) ToolkitThe Accessibility by Design (AbD) in Clinical Research Toolkit is a comprehensive resource intended to be used by sponsors, institutions, investigators, ethics committees/IRBs, participants and Patient advocacy groups to support greater inclusion of people with disabilities in clinical research.

The Accessibility by Design (AbD) in Clinical Research Toolkit is a comprehensive resource intended to be used by sponsors, institutions, investigators, ethics committees/IRBs, participants and Patient advocacy groups to support greater inclusion of people with disabilities in clinical research.

Boehringer Ingelheimhttps://files.constantcontact.com/971a6f79001/01954ce0-d7f2-4967-b711-5ad1bd2259fa.pngDATA TYPES (e.g., electronic health records)http://www.boehringer-ingelheim.com/sites/default/files/Prescription_Medicine/cns_prescription_medicine/DCT_Infographic.pdfDecentralized Clinical Trials for DepressionLiving with depression can mean that people find it hard to socialize or leave their home. Unfortunately, these challenges can make researching this complex condition even more difficult. Boehringer Ingelheim is working in partnership with Science37 to develop and run the first ever decentralized clinical trial for depression.Living with depression can mean that people find it hard to socialize or leave their home. Unfortunately, these challenges can make researching this complex condition even more difficult. Boehringer Ingelheim is working in partnership with Science37 to develop and run the first ever decentralized clinical trial for depression.
Ferringhttps://files.constantcontact.com/971a6f79001/1b9156e3-a7ad-4187-ac6f-080c24c2325e.pngDATA TYPES (e.g., electronic health records)https://www.ferring.com/science-innovation/research-areas/rmmh-equity-grants/Ferring Grants Program for Equity in Reproductive Medicine and Maternal HealthThe Ferring Grants Program for Equity in Reproductive Medicine and Maternal Health aims to fund projects in basic and translational research, clinical research, epidemiology and prevention research and social science research.

The Ferring Grants Program for Equity in Reproductive Medicine and Maternal Health aims to fund projects in basic and translational research, clinical research, epidemiology and prevention research and social science research.

Tevahttps://files.constantcontact.com/971a6f79001/a9f4c006-cdef-475d-a6f3-8f6029e7bc67.pngDATA TYPES (e.g., electronic health records)https://www.tevausa.com/news-and-media/article-pages/digital-equitable-health-alliance/Teva Joins Digital Health for Equitable Health Alliance [DHEH]The coalition aims to address health disparities for low-income, minority and underserved populations through digital health. The DHEH champions policies and programs meant to increase equitable access to quality healthcare by building upon innovations in digital health, telemedicine, wearables, AI, machine learning and more to advance public health and well-being.The coalition aims to address health disparities for low-income, minority and underserved populations through digital health. The DHEH champions policies and programs meant to increase equitable access to quality healthcare by building upon innovations in digital health, telemedicine, wearables, AI, machine learning and more to advance public health and well-being.
Tevahttps://files.constantcontact.com/971a6f79001/a9f4c006-cdef-475d-a6f3-8f6029e7bc67.pngDATA TYPES (e.g., electronic health records)https://youtu.be/Rs13W24BmqQ3 Trends I'm Watching: Shoshi Friedman, Head of Global Clinical Operations Innovative MedicinesClinical trials are essential for the development of safe and effective health care products. Learn more about the latest trends in the sector – from greater accessibility to increased diversity – and why they are essential for growth.

Clinical trials are essential for the development of safe and effective health care products. Learn more about the latest trends in the sector – from greater accessibility to increased diversity – and why they are essential for growth.

Tevahttps://files.constantcontact.com/971a6f79001/a9f4c006-cdef-475d-a6f3-8f6029e7bc67.pngDATA TYPES (e.g., electronic health records)https://www.tevapharm.com/news-and-media/feature-stories/clinical-trial-diversity/Why Diversity in Clinical Trials is So ImportantTeva investigates why it is vital for drug development and outlines its work in this space.

Teva investigates why it is vital for drug development and outlines its work in this space.

Merckhttps://files.constantcontact.com/971a6f79001/17a1b53f-11c9-4b3c-b7c7-46e6f9a2ab66.pngDATA TYPES (e.g., electronic health records)https://blackdoctor.org/blackdoctor-merck-partnership/BlackDoctor.Org and Merck Announce Historic PartnershipBlackDoctor.org (BDO) and Merck are working together to improve Black American participation in clinical trials. Merck was the first to sign on to list its trials on BDO’s Clinical Trials Resource Center (CTRC).

BlackDoctor.org (BDO) and Merck are working together to improve Black American participation in clinical trials. Merck was the first to sign on to list its trials on BDO’s Clinical Trials Resource Center (CTRC).

Merckhttps://files.constantcontact.com/971a6f79001/17a1b53f-11c9-4b3c-b7c7-46e6f9a2ab66.pngDATA TYPES (e.g., electronic health records)https://acrpnet.org/2023/01/12/merck-takes-action-to-address-clinical-research-workforce-challenges/Merck and ACRP CollaborationsThe program aims to introduce the clinical research profession to high school and community college students by offering them ACRP’s Early Talent Training Program™, a comprehensive curriculum to prepare students for a career in the clinical research profession. The program aims to introduce the clinical research profession to high school and community college students by offering them ACRP’s Early Talent Training Program™, a comprehensive curriculum to prepare students for a career in the clinical research profession. 
Merckhttps://files.constantcontact.com/971a6f79001/17a1b53f-11c9-4b3c-b7c7-46e6f9a2ab66.pngDATA TYPES (e.g., electronic health records)https://greenphire.com/news/greenphire-expands-agreement-with-merck-to-help-reduce-financial-and-travel-barriers-for-clinical-trial-participants-worldwide/Greenphire & Merck Help Reduce Financial and Travel Barriers for Clinical Trial Participants WorldwideGreenphire’s ClinCard with rideshare integration is designed to help alleviate financial and logistical burdens on clinical trial participants.Greenphire’s ClinCard with rideshare integration is designed to help alleviate financial and logistical burdens on clinical trial participants.
ZZZZ Articlehttps://files.constantcontact.com/971a6f79001/c2293117-5a46-42f5-adcd-d11e94cd512d.pngWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://pharmanewsintel.com/features/clinical-trial-diversity-inclusion-key-to-advancing-health-equityAdvancing Health Equity with Clinical Trial Diversity: Key StrategiesArticle: Although research has consistently displayed a lack of participant diversity in clinical trials, improving clinical trial diversity is a key strategy for advancing health equity.Article: Although research has consistently displayed a lack of participant diversity in clinical trials, improving clinical trial diversity is a key strategy for advancing health equity.
ZZZZ Articlehttps://files.constantcontact.com/971a6f79001/c2293117-5a46-42f5-adcd-d11e94cd512d.pngWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://ascopubs.org/doi/full/10.1200/EDBK_389838Equitable Access to Clinical Trials: How Do We Achieve It?Study populations for cancer clinical trials do not match the composition of targeted populations for cancer therapies. A variety of changes to clinical trial requirements can improve the accrual of patients from underserved populations to cancer clinical trials.Study populations for cancer clinical trials do not match the composition of targeted populations for cancer therapies. A variety of changes to clinical trial requirements can improve the accrual of patients from underserved populations to cancer clinical trials.
ZZZZ Articlehttps://files.constantcontact.com/971a6f79001/c2293117-5a46-42f5-adcd-d11e94cd512d.pngWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://news.bloomberglaw.com/pharma-and-life-sciences/diversity-in-clinical-trials-at-fda-gets-a-boost-from-new-lawDiversity in Clinical Trials at FDA Gets a Boost From New LawThe 2023 omnibus spending bill (Public Law 117-328) requires diversity action plans for the clinical trials used by the Food and Drug Administration to decide whether drugs are safe and effective.The 2023 omnibus spending bill (Public Law 117-328) requires diversity action plans for the clinical trials used by the Food and Drug Administration to decide whether drugs are safe and effective.
ZZZZ Webinarhttps://2j5d9c.p3cdn1.secureserver.net/wp-content/uploads/2024/01/Webinar.pngWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://bionj.org/bionjs-health-equity-in-clinical-trials-best-practices-webinar-examples-from-which-to-learn-opportunities-for-collaboration/BioNJ’s Health Equity in Clinical Trials Best Practices Webinar Series: Examples from Which to Learn & Opportunities for CollaborationWe are pleased to announce the first webinar in BioNJ’s Health Equity in Clinical Trials Best Practices Webinar Series: Examples from Which to Learn & Opportunities for CollaborationWe are pleased to announce the first webinar in BioNJ’s Health Equity in Clinical Trials Best Practices Webinar Series: Examples from Which to Learn & Opportunities for Collaboration
ZZZZ Webinarhttps://2j5d9c.p3cdn1.secureserver.net/wp-content/uploads/2024/01/Webinar.pngWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://bionj.org/designing-trials-to-broaden-reach-and-expand-diversity-video/BioNJ’s Health Equity in Clinical Trials Best Practices Webinar: Designing Trials to Broaden Reach and Expand DiversityWe are pleased to announce the second webinar in BioNJ’s Health Equity in Clinical Trials Best Practices Webinar Series: Broaden Reach and Expand Diversity in Clinical Trials.We are pleased to announce the second webinar in BioNJ’s Health Equity in Clinical Trials Best Practices Webinar Series: Designing Trials to Broaden Reach and Expand Diversity
Yalehttps://upload.wikimedia.org/wikipedia/commons/thumb/f/f0/Yale_Cancer_Center.svg/346px-Yale_Cancer_Center.svg.pngPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www.yalecancercenter.org/news-article/support-secured-for-yale-cancer-center-consortium-to-advance-equity-in-early-phase-clinical-trials/Yale Cancer Center Consortium to Advance Equity in Early Phase Clinical TrialsThe intent of the Consortium is to help increase access to early phase cancer clinical trials for Patients who would otherwise not have the ability to be treated with novel investigational therapeutic interventions.The intent of the Consortium is to help increase access to early phase cancer clinical trials for Patients who would otherwise not have the ability to be treated with novel investigational therapeutic interventions.
ZZZZ Articlehttps://files.constantcontact.com/971a6f79001/c2293117-5a46-42f5-adcd-d11e94cd512d.pngSITE SELECTION & EXPANSIONhttps://www.pewresearch.org/short-reads/2023/02/10/key-facts-about-black-americans/Site Selection & ExpansionCensus-based diversity calculations include different ethnic group: Hispanic; White; Black or African American; Asian; Native Hawaiian and Other Pacific Islanders. Some sites should be selected in regions where these groups reside. Census-based diversity calculations include different ethnic group: Hispanic; White; Black or African American; Asian; Native Hawaiian and Other Pacific Islanders. Some sites should be selected in regions where these groups reside.
Sanofihttps://files.constantcontact.com/971a6f79001/3d6bca01-ddb0-4243-a7a9-f4e9df3a383a.pngPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www.sanofi.com/en/magazine/our-science/building-a-more-equitable-future-through-inclusive-clinical-trialsBuilding a More Equitable Future through Inclusive Clinical TrialsTo reach diverse Patient groups, we need to engage with new physicians, new trial sites and essentially new communities.To reach diverse Patient groups, we need to engage with new physicians, new trial sites and essentially new communities.
Rutgers Univeristyhttps://ifh.rutgers.edu/wp-content/themes/RUwebsite/img/IFH_RutgersUniversity.pngPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://cohort.rutgers.edu/enThe New Jersey Population Health Cohort StudyThe NJ Population Health Cohort Study was launched in 2022 to improve understanding of how life events and stress affect health, particularly within historically disadvantaged groups, multigenerational families and immigrant groups. The overarching goal of the study is to offer practical, actionable information for improving population health, well-being and health equity.The New Jersey Population Health Cohort Study was launched in 2022 to improve understanding of how life events and stress affect health, particularly within historically disadvantaged groups, multigenerational families, and immigrant groups. The overarching goal of the study is to offer practical, actionable information for improving population health, well-being and health equity in New Jersey and beyond.
Rutgers Cancer Institutehttps://files.constantcontact.com/971a6f79001/77f2d3f2-a5c0-4fec-88a4-31fe2a22b0ea.pngPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://issuu.com/rutgerscancerhealthequity/docs/rutgers_checoe_impactreport_2021_execsummary_r8 Cancer Health Equity Center of Excellence 2021 Executive SummaryAdvancing the achievement of equitable access, improved health care quality and better outcomes across the cancer continuum.Advancing the achievement of equitable access, improved health care quality and better outcomes across the cancer continuum.
Rutgers Cancer Institutehttps://files.constantcontact.com/971a6f79001/77f2d3f2-a5c0-4fec-88a4-31fe2a22b0ea.pngPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www.cinj.org/outreach/cancer-health-equity-center-excellenceCancer Health Equity Center of ExcellenceThe Cancer Health Equity Center of Excellence is a formal partnership between the Rutgers School of Public Health and the Rutgers Cancer Institute of NJ, which will serve as a catalyst for training and education, research, community engagement and public policy advocacy surrounding cancer health equity in one of the nation’s most ethnically and racially diverse states.The Cancer Health Equity Center of Excellence is a formal partnership between the Rutgers School of Public Health and the Rutgers Cancer Institute of NJ, which will serve as a catalyst for training and education, research, community engagement and public policy advocacy surrounding cancer health equity in one of the nation’s most ethnically and racially diverse states.
Regeneronhttps://files.constantcontact.com/971a6f79001/82ef148d-2910-4bec-81a7-c3c68ff81e9d.pngPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www.regeneron.com/downloads/dei-impact-report-2022.pdfMexico City Prospective Study (pg. 22)The MCPS, a study by RGC in collaboration with the Universidad Nacional Autónoma de México and Oxford University, is the largest genomic research study in a Hispanic and LatinX population to date.The MCPS, a study by RGC in collaboration with the Universidad Nacional Autónoma de México and Oxford University, is the largest genomic research study in a Hispanic and LatinX population to date.
PTC Therapeuticshttps://files.constantcontact.com/971a6f79001/36334469-9b79-4c59-bbfc-38633f6dfdad.pngTRIAL SPONSOR (e.g., influence study & protocol design)https://files.constantcontact.com/971a6f79001/99f24e7e-097a-4f65-bfa1-64542301105b.pdfPTC Therapeutics Biomarker Working GroupThe purpose of the PTC Biomarker Working Group is to develop a global, comprehensive biomarker strategy consistent with our mission to provide access to best-in-class treatments for rare disease Patients who have little to no treatment options.The purpose of the PTC Biomarker Working Group is to develop a global, comprehensive biomarker strategy consistent with our mission to provide access to best-in-class treatments for rare disease Patients who have little to no treatment options.
Pfizerhttps://files.constantcontact.com/971a6f79001/6d12ec95-8545-49ca-b6cc-617b877a605a.pngWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2022/story/ensuring-diversity-in-clinical-trials-to-develop-breakthroughs-for-all/Health Equity, Advocacy, and Leadership (HEAL)A partnership with the Tigerlily Foundation to advance education around clinical trials for Black women with breast cancer.A partnership with the Tigerlily Foundation to advance education around clinical trials for Black women with breast cancer.
Pfizerhttps://files.constantcontact.com/971a6f79001/6d12ec95-8545-49ca-b6cc-617b877a605a.pngWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://www.sciencedirect.com/science/article/pii/S1551714423001076A Framework for Setting Enrollment Goals to Ensure Participant Diversity in Sponsored Clinical Trials in the United StatesThe aim of this study was to establish a transparent and reproducible process for setting trial diversity enrollment goals informed by the disease epidemiology.

The aim of this study was to establish a transparent and reproducible process for setting trial diversity enrollment goals informed by the disease epidemiology.

Pfizerhttps://files.constantcontact.com/971a6f79001/6d12ec95-8545-49ca-b6cc-617b877a605a.pngWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://www.businesswire.com/news/home/20240202234166/en/Breaking-Barriers-in-Cancer-Care-The-American-Cancer-Society-and-Pfizer-Announce-a-15-Million-Three-Year-Initiative-to-Bridge-the-Gap-in-Cancer-Care-DisparitiesBreaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care DisparitiesThe initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support in medically underrepresented communities across the United States.

The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support in medically underrepresented communities across the United States.

Pfizerhttps://files.constantcontact.com/971a6f79001/6d12ec95-8545-49ca-b6cc-617b877a605a.pngWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://www.pfizer.com/news/announcements/closing-cancer-care-gap-world-cancer-day-and-beyondClosing the Cancer Care Gap: World Cancer Day and BeyondEvery two seconds, someone in the world is diagnosed with cancer.1 It’s a disease that knows no borders, doesn’t distinguish between race or religion, and pays no mind to whether a person is rich or poor. The great equalizer, it touches every corner of the globe.

Every two seconds, someone in the world is diagnosed with cancer.1 It’s a disease that knows no borders, doesn’t distinguish between race or religion, and pays no mind to whether a person is rich or poor. The great equalizer, it touches every corner of the globe.

Pfizerhttps://files.constantcontact.com/971a6f79001/6d12ec95-8545-49ca-b6cc-617b877a605a.pngWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://www.worldcancerday.org/about/2022-2024-world-cancer-day-campaignWorld Cancer Day 2022-2024 theme: Close the Care GapWorld Cancer Day 2024 the theme is still "Close the Care Gap". The campaign is all about understanding and recognising the inequities in cancer care around the globe. This World Cancer Day, we recognise the power of working together.

World Cancer Day 2024 the theme is still "Close the Care Gap". The campaign is all about understanding and recognising the inequities in cancer care around the globe. This World Cancer Day, we recognise the power of working together.

Pfizerhttps://files.constantcontact.com/971a6f79001/6d12ec95-8545-49ca-b6cc-617b877a605a.pngWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://www.cancer.org/about-us/our-partners/pfizer.htmlThe American Cancer Society and Pfizer: Breaking Barriers in Cancer Care DisparitiesThe American Cancer Society (ACS) and Pfizer launched on February 5th, “Change the Odds: Uniting to Improve Cancer OutcomesTM,” a three-year initiative to address disparities in cancer care. Through $15 million in funding from Pfizer, the initiative aims to improve health outcomes in medically underrepresented communities across the United States by enhancing awareness of and access to cancer screenings, clinical trial opportunities, patient support and comprehensive navigation.

The American Cancer Society (ACS) and Pfizer launched on February 5th, “Change the Odds: Uniting to Improve Cancer OutcomesTM,” a three-year initiative to address disparities in cancer care. Through $15 million in funding from Pfizer, the initiative aims to improve health outcomes in medically underrepresented communities across the United States by enhancing awareness of and access to cancer screenings, clinical trial opportunities, patient support and comprehensive navigation.

Novo Nordiskhttps://www.novartis.com/us-en/themes/custom/nvs_arctic/logo.svgWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://www.novartis.com/us-en/esg/beacon-hopeBeacon of HopeNovartis & the Novartis US Foundation take a major step forward to address the root causes of disparities in health and education by launching Beacon of Hope, an innovative ten-year collaboration with 26 Historically Black Colleges and Universities.Novartis & the Novartis US Foundation take a major step forward to address the root causes of disparities in health and education by launching Beacon of Hope, an innovative ten-year collaboration with 26 Historically Black Colleges and Universities.
Multi-Regional Clinical Trialshttps://2j5d9c.p3cdn1.secureserver.net/wp-content/uploads/2023/09/logo-mrct-center.pngWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://mrctcenter.org/diversity-in-clinical-research/guidance/guidance-document/Achieving Diversity, Inclusion, and Equity in Clinical ResearchThis Guidance Document aims to clarify the importance of, advance the goals of, and provide practical and actionable ways to improve diverse representation of participants in clinical research.This Guidance Document aims to clarify the importance of, advance the goals of, and provide practical and actionable ways to improve diverse representation of participants in clinical research.
Multi-Regional Clinical Trialshttps://2j5d9c.p3cdn1.secureserver.net/wp-content/uploads/2023/09/logo-mrct-center.pngWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://mrctcenter.org/diversity-in-clinical-research/download/1531/Case Study: Multiple Sclerosis Research Mythbusting SeriesHow Accelerated Cure Project (ACP) and the Multiple Sclerosis Association of America (MSAA) collaborated to further diverse clinical trial participation.

How Accelerated Cure Project (ACP) and the Multiple Sclerosis Association of America (MSAA) collaborated to further diverse clinical trial participation.

Multi-Regional Clinical Trialshttps://2j5d9c.p3cdn1.secureserver.net/wp-content/uploads/2023/09/logo-mrct-center.pngWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://mrctcenter.org/diversity-in-clinical-research/download/1529/Case Study: Achieving and Exceeding Clinical Trial Participant Diversity TargetsHow Merck increased clinical trial diversity using Customized Tools, Applications and a Dynamic Enrollment Tracker.

How Merck increased clinical trial diversity using Customized Tools, Applications and a Dynamic Enrollment Tracker.

Novo Nordiskhttps://files.constantcontact.com/971a6f79001/cf3bfcb6-ad0f-45cd-bb27-5c306f9161bb.pngPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www.novonordisk.com/content/dam/nncorp/global/en/sustainable-business/pdfs/driving-change-for-patiens-and-society.pdfReport: Clinical Trials Driving Change for Patients and SocietyThis report examines how Novo Nordisk’s clinical trials also generate value and drive change by nurturing innovation, prioritizing Patient needs and advocating for sustainability.This report examines how Novo Nordisk’s clinical trials also generate value and drive change by nurturing innovation, prioritizing Patient needs and advocating for sustainability.
Novo Nordiskhttps://files.constantcontact.com/971a6f79001/94b944b7-1880-42d9-b63d-e035b7fa8193.pngSCREENING PROCESSES (e.g., decentralized trial technologies)https://www.otsuka-us.com/node/676Use of Spencer® Smart Hub in Clinical Trials and Commercial ApplicationsLeveraging technology to improve diversity and inclusion in clinical research.Leveraging technology to improve diversity and inclusion in clinical research.
Pfizerhttps://files.constantcontact.com/971a6f79001/6d12ec95-8545-49ca-b6cc-617b877a605a.pngPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www.sciencedirect.com/science/article/pii/S1551714421001579Demographic Diversity of Participants in Pfizer Sponsored Clinical Trials in the United StatesTo gain an understanding on the disparity of minority representation in our own studies, we published a landmark, 10-year retrospective analysis (taking data from 2011–2020) of the ethnic, racial, age and gender diversity in our clinical trials.To gain an understanding on the disparity of minority representation in our own studies, we published a landmark, 10-year retrospective analysis (taking data from 2011–2020) of the ethnic, racial, age and gender diversity in our clinical trials.
Pfizerhttps://files.constantcontact.com/971a6f79001/6d12ec95-8545-49ca-b6cc-617b877a605a.pngPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://cdn.pfizer.com/pfizercom/Pfizer_APR_WhitePaper_080921.pdfPfizer Oncology Patient Centricity EcosystemTo provide learnings and best practice suggestions for others seeking to pursue similar efforts, this report provides a detailed overview of how Pfizer and a network of cancer patient advocacy leaders collectively designed processes and built this foundational infrastructure – an ecosystem – for partnering to advance patient centricity.

To provide learnings and best practice suggestions for others seeking to pursue similar efforts, this report provides a detailed overview of how Pfizer and a network of cancer patient advocacy leaders collectively designed processes and built this foundational infrastructure – an ecosystem – for partnering to advance patient centricity.

Novartishttps://files.constantcontact.com/971a6f79001/095c85a1-7c5c-4126-b872-afa334595bb7.pngPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www.researchmatch.org/ResearchMatchResearchMatch is a nonprofit program funded by the National Institutes of Health (NIH). It helps to connect people interested in research studies with researchers from top medical centers across the U.S.ResearchMatch is a nonprofit program funded by the National Institutes of Health (NIH). It helps to connect people interested in research studies with researchers from top medical centers across the U.S.
National Medical Fellowshipshttps://files.constantcontact.com/971a6f79001/f7c3b7ae-df73-43af-b406-d666922e483a.pngWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://nmfonline.org/scholarships-programs/diversity-in-research/clinical-trials-research/National Medical Fellowships Diversity in Clinical Trials Research Program (NMF Dctr)The NMF Dctr seeks to increase the number of clinicians underrepresented in medicine who serve as Principal Investigators, as part of the strategy to increase Patient diversity in clinical trials.The NMF Dctr seeks to increase the number of clinicians underrepresented in medicine who serve as Principal Investigators, as part of the strategy to increase Patient diversity in clinical trials.
Milken Institutehttps://milkeninstitute.org/themes/custom/milken/logo.svgPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://milkeninstitute.org/sites/default/files/2023-04/MappingtheJourneyBuildingaMutualUnderstandingforDiversityandEquityinBiomedicalResearchandClinicalTrials_0.pdfMAPPING THE JOURNEY: Building a Mutual Understanding for Health Equity in Clinical ResearchThe Milken Institute is a nonprofit, nonpartisan think tank focused on accelerating measurable progress on the path to a meaningful life. "MAPPING THE JOURNEY: Building a Mutual Understanding for Health Equity in Clinical Research" was published April 2023.The Milken Institute is a nonprofit, nonpartisan think tank focused on accelerating measurable progress on the path to a meaningful life. "MAPPING THE JOURNEY: Building a Mutual Understanding for Health Equity in Clinical Research" was published April 2023.
Milken Institutehttps://milkeninstitute.org/themes/custom/milken/logo.svgPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://milkeninstitute.org/report/clinical-trials-achieving-diversityAchieving Health Equity: A Multi-Stakeholder Action Plan to Address Diversity across the Clinical Trials Enterprise and the Biomedical Research EcosystemTo drive needed actions forward in a structured and impactful way, FasterCures convened an advisory working group of experts from academia, industry, policy groups, patient advocacy, and disease-specific patient organizations to dive deeper into these issues.To drive needed actions forward in a structured and impactful way, FasterCures convened an advisory working group of experts from academia, industry, policy groups, patient advocacy, and disease-specific patient organizations to dive deeper into these issues.
Merckhttps://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/site-logo.svgWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://www.merck.com/stories/podcast-how-to-bridge-diversity-gaps-in-cancer-clinical-trials/Podcast: How to Bridge Diversity Gaps in Cancer Clinical TrialsLuther Clark talks with Lazarex Cancer Foundation's Dana Dornsife and Marya Shegog about increasing access among historically underrepresented communities.Luther Clark talks with Lazarex Cancer Foundation's Dana Dornsife and Marya Shegog about increasing access among historically underrepresented communities.
Merckhttps://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/site-logo.svgWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://www.merck.com/stories/how-we-foster-innovation-through-our-diverse-workforce/Inspiring Innovation Through Diversity and InclusionBeyond clinical trials, we know commitment to diversity in research starts within, from the people we hire to those we choose as partners.Beyond clinical trials, we know commitment to diversity in research starts within, from the people we hire to those we choose as partners.
Merckhttps://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/site-logo.svgWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://www.merck.com/stories/were-training-more-minority-investigators-to-help-improve-diversity-in-clinical-trials/We’re Training More Minority Investigators to Help Improve Diversity in Clinical TrialsMerck's sponsorship of the National Medical Fellowships’ Diversity in Clinical Trials Research program aims to support and train minority physicians to become principal investigators (PIs) in clinical trials.Merck's sponsorship of the National Medical Fellowships’ Diversity in Clinical Trials Research program aims to support and train minority physicians to become principal investigators (PIs) in clinical trials.
Medidatahttps://files.constantcontact.com/971a6f79001/9aa65425-4b8a-4972-8407-85242f122aa5.pngPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www.medidata.com/en/the-state-of-black-participation-in-clinical-trials-white-paper/The State of Black Participation in Clinical Trials: Evaluating Enrollment TrendsThis analysis covers 972,773 trial participants, 4,003 global trials and various levels of data granularity including global, US, TA and site level analysis. This latest analysis uncovers variation previously masked by aggregate enrollment estimates of Black enrollment in clinical trials.This analysis covers 972,773 trial participants, 4,003 global trials and various levels of data granularity including global, US, TA and site level analysis. This latest analysis uncovers variation previously masked by aggregate enrollment estimates of Black enrollment in clinical trials.
Medidatahttps://files.constantcontact.com/971a6f79001/9aa65425-4b8a-4972-8407-85242f122aa5.pngPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www.medidata.com/en/webinar-walking-the-talk/Walking the Talk: WebinarIndustry thought leaders from Medidata, AbbVie, Emerson Clinical Research and Memorial Sloan Kettering Cancer Center as they share best practices on how to transform trials design, reduce Patient burden and build sustainable community relationships.Industry thought leaders from Medidata, AbbVie, Emerson Clinical Research and Memorial Sloan Kettering Cancer Center as they share best practices on how to transform trials design, reduce Patient burden and build sustainable community relationships.
Medidatahttps://files.constantcontact.com/971a6f79001/9aa65425-4b8a-4972-8407-85242f122aa5.pngPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www.medidata.com/wp-content/uploads/2022/02/FAQs-to-Guide-Your-DCT-Strategy-Jan-22.pdfWhat Are Decentralized Clinical Trials?Find the most frequently asked questions and answers on what decentralized clinical trials mean.Find the most frequently asked questions and answers on what decentralized clinical trials mean.
Jannsenhttps://files.constantcontact.com/971a6f79001/683fc9c1-3815-4b49-837b-044bc7f7cb4c.pngPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www.researchincludesme.com/Research Includes MeJanssen’s Research Includes Me initiative seeks to identify needs, build trust and break down barriers to access, with a particular focus on traditionally underrepresented communities. Research Includes Me provides educational materials, hosts community events and connects Patients to clinical research opportunities.Janssen’s Research Includes Me initiative seeks to identify needs, build trust and break down barriers to access, with a particular focus on traditionally underrepresented communities. Research Includes Me provides educational materials, hosts community events and connects Patients to clinical research opportunities.
Jannsenhttps://files.constantcontact.com/971a6f79001/683fc9c1-3815-4b49-837b-044bc7f7cb4c.pngPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://standuptocancer.org/press/stand-up-to-cancer-announces-5-million-sponsorship-from-janssen-in-support-of-initiative-to-improve-health-equity-in-clinical-trials/#:~:text=A%20%245%20million%20sponsorship%20from%20Janssen%20will%20support,as%20well%20as%20patients%20in%20medically%20underserved%20communities.Stand Up To CancerJanssen Oncology sponsored a $5 million grant with Stand Up to Cancer, a nonprofit organization supporting cancer research, to support the development of initiatives focused on increasing diversity in early phase cancer clinical trials.Janssen Oncology sponsored a $5 million grant with Stand Up to Cancer, a nonprofit organization supporting cancer research, to support the development of initiatives focused on increasing diversity in early phase cancer clinical trials.
Jannsenhttps://files.constantcontact.com/971a6f79001/683fc9c1-3815-4b49-837b-044bc7f7cb4c.pngPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://smdp.icpdprograms.org/project/janssen_sodep/Scholars of Oncology Diversity Engagement Program (Janssen SODEP)Janssen's SODEP program aims to build relationships with ethnically diverse students and post-doctoral researchers to contribute to shaping their career and bring visibility to our job opportunities by providing exposure and mentorship, with the goal of possible job placement.Janssen's SODEP program aims to build relationships with ethnically diverse students and post-doctoral researchers to contribute to shaping their career and bring visibility to our job opportunities by providing exposure and mentorship, with the goal of possible job placement.
Jannsenhttps://files.constantcontact.com/971a6f79001/683fc9c1-3815-4b49-837b-044bc7f7cb4c.pngPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://skinofcolorsociety.org/?s=Diversity+in+Clinical+Research+Mentoring+ProgramJanssen Partnership with the National Medical Association (NMA) Project IMPACT 2.0 Coalition and Skin of Color Society (SOCS)This partnership aims to bridge the clinical trial experience gap. By facilitating a partnership between newly trained NMA investigators, Janssen & SOCS trial investigators/study coordinators, providing new investigators with the knowledge, support & confidence to continue thriving in clinical trial involvement.This partnership aims to bridge the clinical trial experience gap. By facilitating a partnership between newly trained NMA investigators, Janssen & SOCS trial investigators/study coordinators, providing new investigators with the knowledge, support & confidence to continue thriving in clinical trial involvement.
Jannsenhttps://files.constantcontact.com/971a6f79001/683fc9c1-3815-4b49-837b-044bc7f7cb4c.pngPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www.hopkinsmedicine.org/fellowships/programs/dermatology/ethnic-skin-fellowship-programThe JHU Ethnic Skin Program Fellowship (ESP)Janssen’s partnership with ESP addresses the unmet medical needs of skin of color (SOC) Patients by increasing and improving clinical care & advancing research, including training future dermatologists and researchers dedicated to treating skin diseases disproportionately impacting SOC minority populations.Janssen’s partnership with ESP addresses the unmet medical needs of skin of color (SOC) Patients by increasing and improving clinical care & advancing research, including training future dermatologists and researchers dedicated to treating skin diseases disproportionately impacting SOC minority populations.
GSKhttps://www.biospace.com/getasset/21a805d7-9976-446f-97bf-4abb8dcf6ee0/PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www.gsk.com/en-gb/innovation/trials/diversity-in-clinical-trials/Diversity in Clinical Trials | GSKEngaging with communities and advocacy groups to build trust, enhance awareness and provide education and outreach.Engaging with communities and advocacy groups to build trust, enhance awareness and provide education and outreach.
GSKhttps://www.biospace.com/getasset/21a805d7-9976-446f-97bf-4abb8dcf6ee0/PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://tigerlilyfoundation-mylivinglegacy.org/My Living Legacy: Empowering Communities as We Build Trust in Clinical TrialsMy Living Legacy, created in partnership with the Tigerlily Foundation to empower Black and other BIPOC people to more deeply understand and trust in clinical trials and to consider clinical trials as a possible treatment option for life-threatening diseases like breast cancer.

My Living Legacy, created in partnership with the Tigerlily Foundation to empower Black and other BIPOC people to more deeply understand and trust in clinical trials and to consider clinical trials as a possible treatment option for life-threatening diseases like breast cancer.

GSKhttps://www.biospace.com/getasset/21a805d7-9976-446f-97bf-4abb8dcf6ee0/PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://youtu.be/lzgkHXGDr3gImproving Our Clinical Trial Diversity: Ovarian CancerFind out how GSK is working with organizations like MiOra to ensure that women from underserved communities are represented in clinical trials for Ovarian Cancer.

Find out how GSK is working with organizations like MiOra to ensure that women from underserved communities are represented in clinical trials for Ovarian Cancer.

GSKhttps://www.biospace.com/getasset/21a805d7-9976-446f-97bf-4abb8dcf6ee0/PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www.youtube.com/watch?v=JwapXtZ-gyM&t=209sImproving Our Clinical Trial Diversity: Multiple MyelomaMultiple Myeloma disproportionately impacts African Americans. To get ahead of this disease, we're working with patient advocates to increase the number of African American participants in clinical trials.

Multiple Myeloma disproportionately impacts African Americans. To get ahead of this disease, we're working with patient advocates to increase the number of African American participants in clinical trials.

GSKhttps://www.biospace.com/getasset/21a805d7-9976-446f-97bf-4abb8dcf6ee0/PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://journals.sagepub.com/doi/10.1177/17407745221149118Demographic Diversity of US-Based Participants in GSK-Sponsored Interventional Clinical TrialsWe investigate the racial and ethnic demographic diversity of US-based participants in GSK-sponsored interventional trials. We also assess the evaluation of demographic diversity against US Census and epidemiologic data.

We investigate the racial and ethnic demographic diversity of US-based participants in GSK-sponsored interventional trials. We also assess the evaluation of demographic diversity against US Census and epidemiologic data.

Genetechhttps://upload.wikimedia.org/wikipedia/commons/thumb/2/27/Genentech.svg/1200px-Genentech.svg.pngDATA TYPES (e.g., electronic health records)https://www.gene.com/stories/pursuing-a-new-paradigm-in-inclusive-researchTrial PathfinderResults from a research collaboration between Genentech and Stanford known as Trial Pathfinder, published in the scientific journal Nature, highlight how real-world data and AI could be used to help address underrepresentation in clinical research for non-small cell lung cancer.Results from a research collaboration between Genentech and Stanford known as Trial Pathfinder, published in the scientific journal Nature, highlight how real-world data and AI could be used to help address underrepresentation in clinical research for non-small cell lung cancer.
Genetechhttps://upload.wikimedia.org/wikipedia/commons/thumb/2/27/Genentech.svg/1200px-Genentech.svg.pngDATA TYPES (e.g., electronic health records)https://www.gene.com/media/statements/ps_062321Advancing Inclusive Research® Site AllianceThis coalition of clinical research sites will partner with Genentech to advance the representation of diverse Patient populations in the company’s oncology clinical trials, test recruitment and retention approaches and establish best practices that can be leveraged across the industry to help achieve health equity for people with cancer.This coalition of clinical research sites will partner with Genentech to advance the representation of diverse Patient populations in the company’s oncology clinical trials, test recruitment and retention approaches and establish best practices that can be leveraged across the industry to help achieve health equity for people with cancer.
Genetechhttps://upload.wikimedia.org/wikipedia/commons/thumb/2/27/Genentech.svg/1200px-Genentech.svg.pngDATA TYPES (e.g., electronic health records)https://www.gene.com/stories/increasing-diversity-equity-and-inclusion-in-ophthalmology-research?topic=diversity-and-inclusionIncreasing Diversity, Equity And Inclusion In Ophthalmology ResearchA first-of-its-kind retina study called Elevatum for underrepresented Patients with diabetic macular edema.A first-of-its-kind retina study called Elevatum for underrepresented Patients with diabetic macular edema.
FSGhttps://www.fsg.org/wp-content/uploads/2021/08/logo.pngPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www.fsg.org/blog/advancing-health-equity-building-on-fda-requirement-for-clinical-trial-diversity/Advancing Health Equity: How Companies Can Build on the FDA’s Requirement for Clinical Trial Diversity"Advancing Health Equity: How Companies Can Build on the FDA’s Requirement for Clinical Trial Diversity" was released March 2023."Advancing Health Equity: How Companies Can Build on the FDA’s Requirement for Clinical Trial Diversity" was released March 2023.
Eli Lillyhttps://upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Lilly-Logo.svg/726px-Lilly-Logo.svg.png?20230221150444PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www.lilly.com/impact/access-to-medicinesLilly 30x30Lilly 30x30 – to provide improved access to quality health care for 30 million people in resource-limited settings by 2030. https://www.facebook.com/watch/?v=2193548963994688Lilly 30x30 – to provide improved access to quality health care for 30 million people in resource-limited settings by 2030. https://www.facebook.com/watch/?v=2193548963994688
Insmedhttps://insmed.com/wp-content/uploads/2021/11/logo.svgPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://njbiz.com/insmed-enlists-actress-seymour-to-tackle-unseenism-in-health-care/Insmed Enlists Actress Seymour to Tackle ‘Unseenism’ in Health CareInsmed Inc. is teaming up with award-winning actress Jane Seymour for a campaign to raise awareness of gender and age biases in health care.

Insmed Inc. is teaming up with award-winning actress Jane Seymour for a campaign to raise awareness of gender and age biases in health care.

IQVIAhttps://2j5d9c.p3cdn1.secureserver.net/wp-content/uploads/2023/12/IQVIA.pngPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www.iqvia.com/events/2023/04/designing-and-delivering-diversity-in-oncology-clinical-trialsDesigning and Delivering Diversity in Oncology Clinical TrialsThe IQVIA Institute has assembled a multi-stakeholder panel to explore the challenges, key levers and scenarios for consideration in oncology clinical trial diversity planning processes and in designing and delivering those trials.

The IQVIA Institute has assembled a multi-stakeholder panel to explore the challenges, key levers and scenarios for consideration in oncology clinical trial diversity planning processes and in designing and delivering those trials.

IQVIAhttps://2j5d9c.p3cdn1.secureserver.net/wp-content/uploads/2023/12/IQVIA.pngPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www.iqvia.com/library/white-papers/leveraging-real-world-data-to-estimate-race-and-ethnicity-representation-in-clinical-trial-designLeveraging Real-World Data to Estimate Race and Ethnicity Representation in Clinical Trial DesignIQVIA experts evaluate how best to set diversity goals and ensure clinical trials are more accessible by taking a proactive approach to diversity and inclusion that begins at the earliest stages of epidemiological review and protocol design.

IQVIA experts evaluate how best to set diversity goals and ensure clinical trials are more accessible by taking a proactive approach to diversity and inclusion that begins at the earliest stages of epidemiological review and protocol design.

Eli Lillyhttps://upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Lilly-Logo.svg/726px-Lilly-Logo.svg.png?20230221150444PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www.lilly.com/impact/empowering-a-diverse-workforceEmpower A Diverse WorkforceWe believe that by leveraging the varied backgrounds of our more than 35,000 employees – and by driving actionable and measurable strategies to improve DEI, including diversity within our clinical trials – we can better deliver scientific breakthroughs.

We believe that by leveraging the varied backgrounds of our more than 35,000 employees – and by driving actionable and measurable strategies to improve DEI, including diversity within our clinical trials – we can better deliver scientific breakthroughs.

Eli Lillyhttps://upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Lilly-Logo.svg/726px-Lilly-Logo.svg.png?20230221150444PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://atlasclarity.com/lilly-and-nehi-present-equity-in-health-and-health-care-a-roadmap-to-collaborative-action/Lilly and Nehi Present Equity in Health and Health Care: A Roadmap to Collaborative ActionDespite major advancements in health care and medicine, disparities persist in access to health care and health outcomes among racial, ethnic, and other historically marginalized and underserved populations. The health care system is an interconnected ecosystem. Closing disparities requires systematic change and collaboration across a broad coalition of stakeholders.

Despite major advancements in health care and medicine, disparities persist in access to health care and health outcomes among racial, ethnic, and other historically marginalized and underserved populations. The health care system is an interconnected ecosystem. Closing disparities requires systematic change and collaboration across a broad coalition of stakeholders.

Eli Lillyhttps://upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Lilly-Logo.svg/726px-Lilly-Logo.svg.png?20230221150444PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://youtu.be/qYOe8lFnPJADreaming Big: The Future of Mobile ResearchAt the height of the COVID-19 pandemic, we launched mobile research RVs to test a potential COVID therapy in nursing homes across the U.S. Now we’re expanding our fleet of mobile units to improve access to other clinical studies—and transform how we research potential new medicines.

At the height of the COVID-19 pandemic, we launched mobile research RVs to test a potential COVID therapy in nursing homes across the U.S. Now we’re expanding our fleet of mobile units to improve access to other clinical studies—and transform how we research potential new medicines.

Eli Lillyhttps://upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Lilly-Logo.svg/726px-Lilly-Logo.svg.png?20230221150444PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://investor.lilly.com/news-releases/news-release-details/more-two-thirds-people-atopic-dermatitis-and-skin-colorMore than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab studyEli Lilly and Company announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of color and moderate-to-severe atopic dermatitis, commonly called eczema. In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief. 

Eli Lilly and Company announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of color and moderate-to-severe atopic dermatitis, commonly called eczema. In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief. 

Eli Lillyhttps://upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Lilly-Logo.svg/726px-Lilly-Logo.svg.png?20230221150444PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://investor.lilly.com/news-releases/news-release-details/lillys-social-impact-venture-capital-portfolio-poised-grow-300Lilly's Social Impact Venture Capital Portfolio Poised Lilly has allocated an additional $50 million to its $300 million Social Impact Venture Capital Portfolio in efforts to combat racial injustice and its effects on Black Americans and historically marginalized communities in the U.S.Lilly has allocated an additional $50 million to its $300 million Social Impact Venture Capital Portfolio in efforts to combat racial injustice and its effects on Black Americans and historically marginalized communities in the U.S.
Eli Lillyhttps://upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Lilly-Logo.svg/726px-Lilly-Logo.svg.png?20230221150444PATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://investor.lilly.com/news-releases/news-release-details/lilly-unicef-expand-support-help-millions-young-people-riskLilly, UNICEF Expand Support to Help Millions of Young People at Risk of Noncommunicable DiseasesDuring the World Health Assembly today, Eli Lilly and Company (NYSE: LLY) announced it will donate $6.5 million to the United States Fund for UNICEF to expand UNICEF's work to improve the health outcomes of millions of children and youth at risk of noncommunicable diseases (NCDs) living in resource-limited settings in India. This will bring the company's total commitment since 2022 to more than $20 million.During the World Health Assembly today, Eli Lilly and Company (NYSE: LLY) announced it will donate $6.5 million to the United States Fund for UNICEF to expand UNICEF's work to improve the health outcomes of millions of children and youth at risk of noncommunicable diseases (NCDs) living in resource-limited settings in India. This will bring the company's total commitment since 2022 to more than $20 million.
Deloittehttps://www2.deloitte.com/content/dam/assets/logos/Deloitte_logo_PRI.svgDATA TYPES (e.g., electronic health records)https://www2.deloitte.com/us/en/insights/industry/health-care/racial-bias-health-care-algorithms.htmlBias in Health Care Delivery can be Addressed Through a System-Level Approach to Data, Algorithms and TechnologiesLack of data standards makes addressing system-level biases challenging — including collecting data on race/ethnicity, the misuse of racial/ethnic data to inform treatment/diagnosis & algorithms that inappropriately account for race factors.Lack of data standards makes addressing system-level biases challenging — including collecting data on race/ethnicity, the misuse of racial/ethnic data to inform treatment/diagnosis & algorithms that inappropriately account for race factors.
Deloittehttps://www2.deloitte.com/content/dam/assets/logos/Deloitte_logo_PRI.svgDATA TYPES (e.g., electronic health records)https://www2.deloitte.com/us/en/insights/industry/health-care/increasing-diversity-clinical-trials.htmlBroadening Clinical Trial Participation to Improve Health EquityCommunity-based organizations can help reach a broader population and enhance clinical trial diversity. Discover how to meet consumers where they are.Community-based organizations can help reach a broader population and enhance clinical trial diversity. Discover how to meet consumers where they are.
Deloittehttps://www2.deloitte.com/content/dam/assets/logos/Deloitte_logo_PRI.svgDATA TYPES (e.g., electronic health records)https://www2.deloitte.com/us/en/insights/industry/life-sciences/lack-of-diversity-clinical-trials.htmlEnhancing Clinical Trial DiversityStakeholder perspectives on advancing research through representative clinical trialsStakeholder perspectives on advancing research through representative clinical trials.
Deloittehttps://www2.deloitte.com/content/dam/assets/logos/Deloitte_logo_PRI.svgDATA TYPES (e.g., electronic health records)https://www2.deloitte.com/us/en/insights/industry/health-care/community-based-inclusive-and-equitable-clinical-trials.htmlBroadening Research Participation Through Community EngagementCommunity Health Centers can help increase the diversity and scope of clinical studies—and ultimately, improve patient outcomes.Community Health Centers can help increase the diversity and scope of clinical studies—and ultimately, improve patient outcomes.
Deloittehttps://www2.deloitte.com/content/dam/assets/logos/Deloitte_logo_PRI.svgPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/free-public-health-equity-data.htmlDeloitte Health Equity DashboardThe Deloitte Health Equity Dashboard can support individuals and local, regional and national organizations to better understand communities in need.The Deloitte Health Equity Dashboard can support individuals and local, regional and national organizations to better understand communities in need.
Deloittehttps://www2.deloitte.com/content/dam/assets/logos/Deloitte_logo_PRI.svgPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www2.deloitte.com/us/en/insights/industry/health-care/strategies-for-health-equity.html?id=us:2sm:3li:4diUS175982:5awa:6di:MMDDYY:author&pkid=1011049Achieving Health Equity in Life SciencesWith a companywide approach to health equity, life sciences companies can develop more equitable products and services—and see better health outcomes and tangible business benefits.With a companywide approach to health equity, life sciences companies can develop more equitable products and services—and see better health outcomes and tangible business benefits.
Deloittehttps://www2.deloitte.com/content/dam/assets/logos/Deloitte_logo_PRI.svgPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www2.deloitte.com/us/en/blog/health-care-blog/2022/using-ai-to-accelerate-clinical-trials.htmlUsing AI to Accelerate Clinical TrialsUnlocking the Potential: AI's game-changing role in life sciences accelerates drug development, streamlining clinical trials for faster delivery of life-saving treatments.Unlocking the Potential: AI's game-changing role in life sciences accelerates drug development, streamlining clinical trials for faster delivery of life-saving treatments.
Crossroads 4 Hopehttps://crossroads4hope.org/wp-content/uploads/2023/01/Crossroads4Hope-Logo-new-copy-NX-1.pngPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://crossroads4hope.org/outreach-initiative/Building Community Resilience: Closing The Cancer Care GapCrossroads4Hope helps save lives by closing the cancer care gap in vulnerable communities, activating Health Champions as “First Responders” who normalize conversations around cancer, treatment decision-making and clinical trials.Crossroads4Hope helps save lives by closing the cancer care gap in vulnerable communities, activating Health Champions as “First Responders” who normalize conversations around cancer, treatment decision-making and clinical trials.
Bristol Myers Squibbhttps://s25.q4cdn.com/566753351/files/design/bms-rebrand-logo.svgWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://diversityinclinicaltrials.orgRobert A. Winn Diversity in Clinical Trials Award Program (Bristol Myers Squibb Foundation)The program aims to transform the U.S. clinical research landscape by training 250 new, community-oriented clinical trialists, to bring in the community voice at every phase of clinical and translational research, and increase DICT.The program aims to transform the U.S. clinical research landscape by training 250 new, community-oriented clinical trialists, to bring in the community voice at every phase of clinical and translational research, and increase DICT.
Bristol Myers Squibbhttps://s25.q4cdn.com/566753351/files/design/bms-rebrand-logo.svgWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://news.bms.com/news/philanthropy/2023/Bristol-Myers-Squibb-Announces-Progress-Toward-Long-Term-Inclusion--Diversity-Goals-and-Health-Equity-Commitments/default.aspxBristol Myers Squibb Inclusion & Diversity and Health Equity Commitments (Diversity in Clinical Trials Goal)In 2020, BMS set I&D and health equity goals including one for diversity in clinical trials which aimed to locate 25% BMS clinical trials in the United States in racially and ethnically diverse communities by 2022 and 58% has been achieved to dateIn 2020, BMS set I&D and health equity goals including one for diversity in clinical trials which aimed to locate 25% BMS clinical trials in the United States in racially and ethnically diverse communities by 2022 and 58% has been achieved to date
Bristol Myers Squibbhttps://s25.q4cdn.com/566753351/files/design/bms-rebrand-logo.svgWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://www.bms.com/life-and-science/news-and-perspectives/patient-engagement-and-clinical-trial-diversity.htmlPatient Expert Engagement Resource (PEER)Bristol Myers Squibb works with Patient advocates through PEER to formally incorporate Patient voices at every stage in R&D and commercialization. All pivotal trial protocols must include expert Patient advocate engagement for sign off.Bristol Myers Squibb works with Patient advocates through PEER to formally incorporate Patient voices at every stage in R&D and commercialization. All pivotal trial protocols must include expert Patient advocate engagement for sign off.
Bristol Myers Squibbhttps://s25.q4cdn.com/566753351/files/design/bms-rebrand-logo.svgWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Launches-Disability-Diversity-in-Clinical-Trials-DDiCT-Initiative-to-Improve-Healthcare-Outcomes-for-People-with-Disabilities/default.aspxDisability Diversity in Clinical Trials (DDiCT) InitiativeThe initiative initially aims to make recommendations on how to effectively improve access, engagement, speed of enrollment and participation of people with disabilities in clinical trials in collaboration with Disability Solutions.The initiative initially aims to make recommendations on how to effectively improve access, engagement, speed of enrollment and participation of people with disabilities in clinical trials in collaboration with Disability Solutions.
Bristol Myers Squibbhttps://s25.q4cdn.com/566753351/files/design/bms-rebrand-logo.svgWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://www.bms.com/researchers-and-partners/clinical-trials-and-research.htmlSOGI data collection in clinical trialsIn 2022, the company launched an initiative to collect voluntary Patient gender self-identification data in clinical trials to improve culturally competent care for LGBT patients and increase inclusive research and DICT.Clinical trials and research are a critical part of bringing new medicines to patients. Through the data generated from clinical trials, we answer important scientific questions and gain a better understanding about the efficacy and safety of these study medicines and their potential as treatment options for patients.
Biomarinhttps://www.biomarin.com/wp-content/uploads/2020/07/biomarin.svgPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www.biomarin.com/our-company/corporate-social-responsibility/diversity-equity-inclusion/clinical-trial-diversity/BioMarin CTD Working GroupA CTD Working Group, comprised of cross-functional leaders in clinical trial design and conduct.A CTD Working Group, comprised of cross-functional leaders in clinical trial design and conduct.
Biogenhttps://www.biogen.com/content/dam/corporate/international/global/en-US/global/logos/biogen-logo-colour.svgPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www.biogen.com/stories/tufts-clinical-trial.htmlA Collaboration with Tufts Center for the Study of Drug DevelopmentThe study investigated ways to potentially help improve a fundamental step in future healthcare outcomes — clinical trials.The study investigated ways to potentially help improve a fundamental step in future healthcare outcomes — clinical trials.
ASCPThttps://files.constantcontact.com/971a6f79001/6fb9a9a1-e5f4-4518-89d2-80cb83a38532.pngTRIAL SPONSOR (e.g., influence study & protocol design)https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.2819The Clinical Trials Transformation InitiativeThe Clinical Trials Transformation Initiative (CTTI)—a public-private partnership between Duke University and the FDA—investigated existing organizational-level diversity and inclusion practices among institutions who sponsor and lead clinical trials of investigational medical products.The Clinical Trials Transformation Initiative (CTTI)—a public-private partnership between Duke University and the FDA—investigated existing organizational-level diversity and inclusion practices among institutions who sponsor and lead clinical trials of investigational medical products.
Amicushttps://amicusrx.com//wp-content/uploads/2017/09/logo.pngPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://amicusrx.com/wp-content/uploads/2023/04/Amicus-ESG2023-FINAL.pdfAssessing Capacity for Diverse Rare Disease Clinical TrialsWe are currently assessing our capacity for supporting diversity in rare disease clinical trials across our partner sites. We have also solicited RFPs from vendors with a strong background in supporting diverse clinical trial recruitment.We are currently assessing our capacity for supporting diversity in rare disease clinical trials across our partner sites. We have also solicited RFPs from vendors with a strong background in supporting diverse clinical trial recruitment.
Amagenhttps://www.amgen.com/-/media/Themes/CorporateAffairs/amgen-com/amgen-com/images/amgencommigration/Common/amgen-blue.svg?la=en&hash=7D2AC78653B168ACF5B939261E70935FPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www.amgen.com/stories/2021/05/-/media/Themes/CorporateAffairs/amgen-com/amgen-com/images/amgencommigration/stories/2021/05-10-Building-Partnerships-to-Disrupt-Health-Barriers/2021-Amgen-Health-Equity-Summit-Exec-Summary-FINAL.pdfDisrupting Health Disparities Through PartnershipAmgen's Summit, Disrupting Health Disparities Through Partnership, brought together a wide range of experts to discuss issues around racial equity in healthcare.Amgen's Summit, Disrupting Health Disparities Through Partnership, brought together a wide range of experts to discuss issues around racial equity in healthcare.
Amagenhttps://www.amgen.com/-/media/Themes/CorporateAffairs/amgen-com/amgen-com/images/amgencommigration/Common/amgen-blue.svg?la=en&hash=7D2AC78653B168ACF5B939261E70935FPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www.amgen.com/stories/2021/02/inside-amgens-push-for-greater-diversity-in-clinical-trialsRISE (Representation in ClInical ReSEarch)RISE (Representation in ClInical ReSEarch) is a team dedicated to addressing the systemic issues that deter people from participating in research, especially those who have been historically excluded due to race, ethnicity, sex, age and other factors.RISE (Representation in ClInical ReSEarch) is a team dedicated to addressing the systemic issues that deter people from participating in research, especially those who have been historically excluded due to race, ethnicity, sex, age and other factors.
Abbviehttps://www.abbvie.com/content/dam/abbvie-com2/images/logos/abbvie-logo-header.svgPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www.abbvie.com/who-we-are/our-stories/are-your-needs-represented-in-clinical-trials.htmlMeet Patients Where They AreClinical trial participation should reflect the Patient population affected by the disease. AbbVie's head of diversity and Patient inclusion looks at what needs to be done to progress future clinical research efforts.Clinical trial participation should reflect the Patient population affected by the disease. AbbVie's head of diversity and Patient inclusion looks at what needs to be done to progress future clinical research efforts.
Abbotthttps://upload.wikimedia.org/wikipedia/commons/thumb/a/a4/Abbott_Laboratories_logo.svg/800px-Abbott_Laboratories_logo.svg.png?20200420035815WORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://www.abbott.com/corpnewsroom/sustainability/new-scholarships-support-diverse-researchers-of-the-future.htmlAbbott Scholars Scholarship Abbott commits $5 million to fund nearly 300 scholarships through new partnerships with medical schools at historically black colleges and universities (HBCUs) and nursing associations.Abbott commits $5 million to fund nearly 300 scholarships through new partnerships with medical schools at historically black colleges and universities (HBCUs) and nursing associations.
Abbotthttps://upload.wikimedia.org/wikipedia/commons/thumb/a/a4/Abbott_Laboratories_logo.svg/800px-Abbott_Laboratories_logo.svg.png?20200420035815WORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://abbott.mediaroom.com/2022-05-11-Abbott-and-Women-as-One-Partner-to-Help-More-Underrepresented-Physicians-Lead-Clinical-TrialsAbbott and Women as One Partner to Help More Underrepresented Physicians Lead Clinical TrialsAbbott partnered with Women as One to train more female and underrepresented physicians to pursue clinical trial research and help recruit clinical trial participants from historically underrepresented groups.Abbott partnered with Women as One to train more female and underrepresented physicians to pursue clinical trial research and help recruit clinical trial participants from historically underrepresented groups.
Abbotthttps://upload.wikimedia.org/wikipedia/commons/thumb/a/a4/Abbott_Laboratories_logo.svg/800px-Abbott_Laboratories_logo.svg.png?20200420035815WORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://www.abbott.com/corpnewsroom/sustainability/case-study-clinical-trial-diversity-for-life-btk.htmlCase Study: Clinical Trial Diversity for LIFE-BTKA case study of recruiting Patients in underserved communities.A case study of recruiting Patients in underserved communities.
AAHCIhttps://files.constantcontact.com/971a6f79001/b7abfd5b-d09d-4267-bc38-f7afbc7fa1ac.pngWORKFORCE DEVELOPMENT (e.g., investigator education & diversity)https://www.aahcdc.org/Publications-Resources/Series/Connecting-Pipelines-to-Pathways-for-Health-Equity-Case-StudiesConnecting Pipelines to Pathways for Health Equity: Case StudiesThis series of case studies in the Academic Health Center Best Practices showcase pipeline & pathway programs developed at academic health centers to inspire and support learners to enter health professions and biomedical sciences careers. Each case study details a specific challenge, the institution’s response, key takeaways and outcomes.This series of case studies in the Academic Health Center Best Practices showcase pipeline & pathway programs developed at academic health centers to inspire and support learners to enter health professions and biomedical sciences careers. Each case study details a specific challenge, the institution’s response, key takeaways and outcomes.
AAFP5https://files.constantcontact.com/971a6f79001/cdce8ee8-8cff-44df-90e8-37d60d0b17c5.pngPATIENT RECRUITMENT, ENGAGEMENT & COMMUNITY OUTREACHhttps://www.aafp.org/pubs/fpm/issues/2023/0300/health-equity.htmlCase Studies in Innovative Community Engagement to Improve Health Equity in Cardiovascular DiseaseBeginning in March 2021, the American Academy of Family Physicians (AAFP) implemented a two-year project to address cardiovascular disparities in African American communities, with a focus on atrial fibrillation (AFib).Beginning in March 2021, the American Academy of Family Physicians (AAFP) implemented a two-year project to address cardiovascular disparities in African American communities, with a focus on atrial fibrillation (AFib).